series	seriesDescription	geoAreaCode	geoAreaName	timePeriodStart	value	valueType	time_detail	upperBound	lowerBound	basePeriod	source	footnotes	Nature	Units	Reporting Type
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	2012.0	37	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	2013.0	52	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	2014.0	58	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	2015.0	74	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	2016.0	97	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	2017.0	98	Float					WHO/UNICEF coverage estimates 2017 revision, July 2018	['']	E	PERCENT	G
